- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Transcript:
What are some best practices for choosing biologics for patients with different dermatological conditions?
For patients who come in to see us who have various conditions, we really try to tailor the biologic treatment to their needs. I don't have an algorithm where I always put every patient on drug X and then drug Y and then drug Z. I really try to hear what's most important to the patient. Is it certain side effects that they're having that they're worried about, or frequency of injections of medication? In that way, we can try to make sure that we give them the best possible treatment that meets their goals.
What can you tell us about your latest research on the efficacy and safety of ruxolitinib cream monotherapy for vitiligo?
So today [Saturday], we released the results of the TRuE-V1 and TRuE-V2 phase 3 program for topical ruxolitinib cream in vitiligo through Week 52. What it showed is that patients get enhanced pigmentation beyond the 6-month mark, with continued improvement through the year.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
